Evidence map›Paper›PMID 28445153›Full record

ArticleOncotarget2017

Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes.

Elise Furet, Morad El Bouchtaoui, Jean-Paul Feugeas, Catherine Miquel, Christophe Leboeuf, Clémentine Beytout, Philippe Bertheau, Emilie Le Rhun, Jacques Bonneterre, Anne Janin and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Elise FuretUniversité Paris Diderot, Inserm, Paris, France.
Morad El BouchtaouiINSERM, U1165-Paris, France.
Jean-Paul FeugeasINSERM, U1137-Paris, France.
Catherine MiquelUniversité Paris Diderot, Inserm, Paris, France.
Christophe LeboeufUniversité Paris Diderot, Inserm, Paris, France.
Clémentine BeytoutINSERM, U1165-Paris, France.
Philippe BertheauUniversité Paris Diderot, Inserm, Paris, France.
Emilie Le RhunCentre Oscar Lambret, Département de Sénologie, Lille, France.
Jacques BonneterreCentre Oscar Lambret, Département de Sénologie, Lille, France.
Anne JaninUniversité Paris Diderot, Inserm, Paris, France.
Guilhem BousquetUniversité Paris Diderot, Inserm, Paris, France.
Inserm · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Lille · FRCentre Oscar Lambret · FRHôpital Saint-Louis · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetastatic breast cancer is a leading cause of mortality in women, partly on account of brain metastases. However, the mechanisms by which cancer cells cross the blood-brain barrier remain undeciphered. Most molecular studies predicting metastatic risk have been performed on primary breast cancer samples. Here we studied metastatic lymph-nodes from patients with breast cancers to identify markers associated with the occurrence of brain metastases.

resultsTranscriptomic analyses identified CDKN2A/p16 as a gene potentially associated with brain metastases. MATERIALS AND

methodsFifty-two patients with HER2-overexpressing or triple-negative breast carcinoma with lymph nodes and distant metastases were included in this study. Transcriptomic analyses were performed on laser-microdissected tumor cells from 28 metastatic lymph-nodes. Supervised analyses compared the transcriptomic profiles of women who developed brain metastases and those who did not. As a validation series, we studied metastatic lymph-nodes from 24 other patients.Immunohistochemistry investigations showed that p16 mean scores were significantly higher in patients with brain metastases than in patients without (7.4 vs. 1.7 respectively, p < 0.01). This result was confirmed on the validation series. Multivariate analyses showed that the p16 score was the only variable positively associated with the risk of brain metastases (p = 0.01).With the same threshold of 5 for p16 scores using a Cox model, overall survival was shorter in women with a p16 score over 5 in both series.

conclusionsThe risk of brain metastases in women with HER2-overexpressing or triple-negative breast cancer could be better assessed by studying p16 protein expression on surgically removed axillary lymph-nodes.

Indexed as

AdultAgedBiomarkers, TumorBlood-Brain BarrierBrain NeoplasmsCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Erb-b2 Receptor Tyrosine KinasesFemaleHumansLymphatic MetastasisLymph NodesMiddle AgedRiskSurvival AnalysisTranscriptomeBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18ERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesbrain metastasesbreast cancerp16

Identifiers

PMID28445153
PMCPMC5514912
OpenAlexW2604741968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.